Background: Remdesivir is widely used for treatment of SARS-CoV-2 pneumonia. The aim of this study was to evaluate the characteristics of patients with moderate-to-severe COVID-19 treated with remdesivir, and their outcomes during hospitalization. Methods: This retrospective observational multicenter study included consecutive patients, hospitalized for moderate-to-severe COVID-19 (September 2020—September 2021), who were treated with remdesivir. Results: One thousand four patients were enrolled, all with onset of symptoms occurring less than 10 days before starting remdesivir; 17% of patients had 4 or more concomitant diseases. Remdesivir was well tolerated, adverse drug reactions (ADRs) being reported in 2.3% of patients. In-hospital death occurred in 80 patients (8.0%). The median timing of the first remdesivir dose was 5 days after symptom onset. The following endpoints did not differ according to the time span from the onset of symptoms to the first dose: length of hospitalization, in-hospital death, composite outcome (in-hospital death and/or endotracheal intubation). Advanced age, number of comorbidities ≥ 4, and severity of respiratory failure at admission were associated with poor in-hospital outcomes. Conclusion: In a real-world setting, remdesivir proved to be a safe and well-tolerated treatment for moderate-to-severe COVID-19. In patients receiving remdesivir less than 3 or 5 days from the onset of SARS-CoV-2 symptoms, mortality and the need for mechanical ventilation did not differ from the rest of the sample.
Real-world use of remdesivir for the treatment of patients admitted to Italian hospitals with COVID-19: the nationwide retrospective FADOI-RECOVER study / Pieralli, Filippo; Pomero, Fulvio; Dentali, Francesco; Norbiato, Claudio; Attardo, Tiziana; Vicari, Susanna; Magnani, Elena; Marzilli, Maria Antonietta; Piccolo, Paola; Valerio, Antonella; Manfellotto, Dario; Null, Null; Brugiotti, Elena; Carella, Vincenzo; Coppo, Martina; Ferrando, Francesca; Lauritano, Marta.; Marchetti, Bruno; Vitale, Francesco; Gasperina, Daniela Dalla; Baroni, Elena; Boccatonda, Andrea; Giorgini, Enrico; Milite, Teresa; Montaguti, Luca; Cagnoni, Elisa; Mogavero, Giulia; Capoccetta, Giovanni; De Giovanni, Raffaella; Martelli, Francesca; Guazzini, Giulia; Grassi, Alberto; Romani, Laura; Gnerre, Paola; Mastroianni, Franco; D'Onofrio, Fabiana; Berra, Sergio; Pozzoli, Simona; Bobbio, Flavio; Bianco, Sara; Re, Azzurra; Liberato, Nicola; Job, Sara; Antonucci, Giancarlo; Para, Ombretta; Ferrara, Gino; Giordano, Antonietta; Falco, Olga; Manetti, Roberto; Bologna, Carolina; Buscaglia, Sandra; Oliviero, Cristina; Amitrano, Maria; Iorio, Valeria; Tibullo, Loredana; Ferrari, Giovanni; Brandolini, Micaela; Leone, Giovanna; Usai, Carlo; Manzoni, Noemi Elisabetta; Di Stefano, Rita; Renna, Eusapia. - In: BMC INFECTIOUS DISEASES. - ISSN 1471-2334. - 23:1(2023). [10.1186/s12879-023-08422-6]
Real-world use of remdesivir for the treatment of patients admitted to Italian hospitals with COVID-19: the nationwide retrospective FADOI-RECOVER study
Falco, Olga;Manetti, Roberto;Usai, Carlo;
2023-01-01
Abstract
Background: Remdesivir is widely used for treatment of SARS-CoV-2 pneumonia. The aim of this study was to evaluate the characteristics of patients with moderate-to-severe COVID-19 treated with remdesivir, and their outcomes during hospitalization. Methods: This retrospective observational multicenter study included consecutive patients, hospitalized for moderate-to-severe COVID-19 (September 2020—September 2021), who were treated with remdesivir. Results: One thousand four patients were enrolled, all with onset of symptoms occurring less than 10 days before starting remdesivir; 17% of patients had 4 or more concomitant diseases. Remdesivir was well tolerated, adverse drug reactions (ADRs) being reported in 2.3% of patients. In-hospital death occurred in 80 patients (8.0%). The median timing of the first remdesivir dose was 5 days after symptom onset. The following endpoints did not differ according to the time span from the onset of symptoms to the first dose: length of hospitalization, in-hospital death, composite outcome (in-hospital death and/or endotracheal intubation). Advanced age, number of comorbidities ≥ 4, and severity of respiratory failure at admission were associated with poor in-hospital outcomes. Conclusion: In a real-world setting, remdesivir proved to be a safe and well-tolerated treatment for moderate-to-severe COVID-19. In patients receiving remdesivir less than 3 or 5 days from the onset of SARS-CoV-2 symptoms, mortality and the need for mechanical ventilation did not differ from the rest of the sample.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
